References
- Ventura SJ, Peters KD, Martin JA, et al. Births and deaths: United States, 1996. Mon Vital Stat Rep 1997: 46(1 Suppl 2): 1–40
- Wellford AL, Ashcom TL, Whitney EJ, et al. Changing presentation of coronary heart disease in an inpatient population within the US military health care system. Mil Med 1993; 158(9): 598–603
- Fuster V, Badimon L, Cohen M, et al. Insights into the pathogenesis of acute ischemic syndromes. Circulation 1988; 77(6): 1213–20
- Théroux P, Fuster V. Acute coronary syndromes: unstable angina and non-Q wave myocardial infarction. Circulation 1998; 97: 1195–206
- Willerson JT, Buja LM. Q wave versus non-Q wave myocardial infarction. Cardiovasc Clin 1989; 20(1): 183–95
- Nicod P, Gilpin E, Dittrich H, et al. Short- and long-term clinical outcome after Q wave and non-Q wave myocardial infarction in a large patient population. Circulation 1989; 79: 528–36
- Aguirre FV, Younis LT, Chaitman BR, et al. Early and 1-year clinical outcome of patients' evolving non-Q wave versus Q wave myocardial infarction after thrombolysis: results from the TIMI II Study. Circulation 1995; 91(10): 2541–8
- ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2(8607): 349–60
- Jugdutt BI, Warnica JW. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications: effect of timing, dosage and infarct location. Circulation 1988; 78: 906–19
- Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular- weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337(7): 447–52
- Oler A, Whooley MA, Oler J, et al. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis. JAMA 1996; 276(10): 811–5
- Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327(10): 669–77
- Konstam MA, Rousseau MF, Kronenberg MW, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. Circulation 1992; 86(2): 431–8
- Gibson RS, Boden WE, Theroux P, et al. Diltiazem and reinfarction in patients with non-Q wave myocardial infarction. N Engl J Med 1986; 315(7): 423–9
- Rodda BE. The timolol myocardial infarction study: an evaluation of selected variables. Circulation 1983; 67(Suppl 1): 1–101–6
- Gheorghiade M, Schultz L, Tilley B, et al. Effects of propranolol in non-Q wave acute myocardial infarction in the beta blocker heart attack trial. Am J Cardiol 1990; 66: 129–33
- The MIAMI Trial Research Group. Mortality. Am J Cardiol 1985; 56: 15G–22G
- The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q wave myocardial infarction: results of the TIMI IIIB trial. Circulation 1994; 89(4): 1545–56
- Boden WE, O'Rourke RA, Crawford MH, et al. Outcomes in patients with acute non-Q wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. N Engl J Med 1998; 338(25): 1785–92
- The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction. N Engl J Med 1998; 338(21): 1488–97
- Brener SJ, Barr LA, Burchenal JEB, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 1998, 98(8): 734–41
- The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339(7): 436–43